Drug Trial Radar · NCT04676048
ASC618 Gene Therapy in Hemophilia A Patients
Last checked: Nov 19, 2026Latest source record: Feb 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Aug 3, 2022
Primary completion
Dec 2023
Study completion Dec 2026
Sponsor
- Lead sponsor
- ASC TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Currently, hemophilia A patients are managed with prophylactic or on-demand replacement therapy with recombinant FVIII or alternative therapeutics. The major challenges of current treatment regimens, such as the short half-life of hemophilia therapeutics with the need for frequent IV injections, encourage the current efforts for gene transfer therapy. This study will evaluate the safety and preliminary efficacy of ASC618, an AAV vector encoding B-domain deleted codon-optimized human factor VIII under a synthetic liver-directed promoter
Conditions
- Hemophilia A
Interventions
ASC618Biological
ASC618 will be given as a single IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adverse events, and serious AEsTime frame: 12 months post-infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.